Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of the Phase I TACTIC-2 trial (NCT04727151) of TAC01-HER2, a novel HER2-directed TAC T-cell therapy, in a variety of solid tumors. The primary endpoint of dose limiting toxicity was reached, and a transient complete response was reported in patients with gastric cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.